Wegovy Cost in Massachusetts 2026: Prices, Insurance, and Savings

What Wegovy Actually Costs at Massachusetts Pharmacies

The wholesale acquisition cost (WAC) set by Novo Nordisk for Wegovy is $1,349 per month across all doses during the titration and maintenance phases. Massachusetts retail pharmacies, including CVS, Walgreens, and independent pharmacies across Boston, Worcester, Springfield, and Cape Cod, charge cash-pay prices that closely mirror this list price, typically ranging from $1,300 to $1,450 depending on location and any in-house discount programs.

This price covers four prefilled pens (one per week). The FDA-approved prescribing information specifies a 16-week dose escalation starting at 0.25 mg weekly and increasing to the 2.4 mg maintenance dose [1]. Each dose level requires its own pen strength, so patients fill a new prescription monthly throughout titration.

For context, a 2022 analysis in JAMA Network Open found that the U.S. list prices of GLP-1 receptor agonists were three to nine times higher than in peer countries [2]. That gap persists in 2026. Massachusetts residents paying out of pocket face the same national pricing reality: the list price has not dropped since Wegovy's June 2021 approval.

Pharmacy benefit managers (PBMs) negotiate confidential rebates with Novo Nordisk, so the net cost to insurers is lower than $1,349. But those rebates do not reduce the price at the counter for uninsured patients. The Congressional Budget Office has noted that GLP-1 RA spending is among the fastest-growing categories in both Medicare and commercial plans [3].

Massachusetts Medicaid Coverage for Wegovy

Massachusetts Medicaid (MassHealth) covers Wegovy with prior authorization. This makes Massachusetts one of a growing number of states where Medicaid beneficiaries can access semaglutide 2.4 mg for chronic weight management without a blanket exclusion.

Prior authorization requirements typically include documentation of a BMI ≥30 kg/m², or BMI ≥27 kg/m² with at least one weight-related comorbidity such as type 2 diabetes, hypertension, or dyslipidemia. The prescriber must also document a failed trial of lifestyle modification. The Endocrine Society's 2024 clinical practice guideline on pharmacologic management of obesity recommends GLP-1 RAs as first-line pharmacotherapy for adults with obesity and supports their coverage by public payers [4].

MassHealth may require step therapy or quantity limits. Patients should confirm current formulary status through the MassHealth Drug List, as coverage terms change during annual formulary reviews. A 2023 study in Obesity found that Medicaid coverage of anti-obesity medications varied widely by state and that prior authorization requirements were the most common barrier [5].

Approval timelines in Massachusetts typically run 5 to 15 business days. If denied, patients can appeal. The American Academy of Family Physicians (AAFP) position statement supports removing administrative barriers to anti-obesity medication access [6].

Which Massachusetts Insurance Plans Cover Wegovy

Commercial insurers in Massachusetts have adopted Wegovy coverage at different speeds. Blue Cross Blue Shield of Massachusetts, Harvard Pilgrim Health Care, Tufts Health Plan, and Aetna plans sold in Massachusetts all list Wegovy on their formularies in 2026, though tier placement and cost-sharing vary.

Most plans place Wegovy on a specialty or non-preferred brand tier, which means higher copays or coinsurance (often 25% to 50% of the negotiated price). A patient with 30% coinsurance on a $1,349 list price faces roughly $405 per month before any manufacturer assistance. Plans that classify Wegovy as a preferred brand may charge a flat copay of $50 to $150.

Self-insured employer plans, which cover the majority of commercially insured workers in Massachusetts, set their own formulary rules. Some exclude anti-obesity medications entirely. The CDC's data on obesity prevalence shows Massachusetts has an adult obesity rate of approximately 25%, lower than the national average but still representing over 1.3 million adults [7].

Patients should call the number on their insurance card and ask two questions: "Is Wegovy on formulary?" and "What is my cost-sharing at a preferred pharmacy?" A 2024 survey published in the Annals of Internal Medicine found that fewer than half of patients prescribed GLP-1 RAs filled the prescription within 30 days, with cost cited as the primary barrier [8].

How the Novo Nordisk Savings Card Works in Massachusetts

Novo Nordisk offers a manufacturer savings card that reduces copays for commercially insured patients. Eligible patients pay as little as $0 per month for Wegovy, with Novo Nordisk covering the remaining copay up to a set maximum (terms change periodically, but recent iterations cap total annual benefit around $500 per fill or $6,000 annually).

Eligibility rules exclude patients with government insurance, including Medicare, Medicaid, Tricare, and VA benefits. Massachusetts residents with MassHealth cannot use the savings card. The card also requires that the patient's commercial plan already covers Wegovy; it does not function as a standalone discount for uninsured patients.

To activate the card, patients register through the Wegovy savings program page on Novo Nordisk's website or receive a card through their prescriber's office [9]. The pharmacist processes it as a secondary payer at the point of sale.

A key limitation: the savings card may not apply at all pharmacies. Some PBMs restrict copay accumulator or copay maximizer programs, meaning the manufacturer's payment may not count toward the patient's annual deductible or out-of-pocket maximum. Massachusetts does not currently have a state law banning copay accumulator programs, unlike a handful of other states. Patients should verify with their insurer whether manufacturer assistance counts toward their deductible.

Compounded Semaglutide 2.4 mg in Massachusetts: Cost and Legality

Compounded semaglutide 2.4 mg is available in Massachusetts through licensed 503A compounding pharmacies. These pharmacies prepare patient-specific formulations based on a valid prescription. Prices start around $199 per month, a fraction of the $1,349 brand-name cost.

The legality of compounded semaglutide hinges on FDA enforcement discretion regarding drugs on or off the FDA drug shortage list. When semaglutide appeared on the shortage list, 503A and 503B compounders produced it under the Federal Food, Drug, and Cosmetic Act exemptions. As of 2026, the FDA's position on compounded semaglutide has shifted multiple times, and patients should confirm their compounder's current compliance status [10].

Massachusetts requires compounding pharmacies to hold a valid Board of Registration in Pharmacy license. The state adopted stricter oversight after the 2012 New England Compounding Center (NECC) meningitis outbreak, which originated in Framingham, Massachusetts, and resulted in federal legislation creating the DQSA (Drug Quality and Security Act) [11]. Patients using compounded semaglutide should verify that the pharmacy is state-licensed, operates under a 503A or 503B designation, and sources pharmaceutical-grade semaglutide base.

Compounded formulations may differ from brand Wegovy in concentration, injection volume, and device. They are not FDA-approved, and the STEP-1 trial data establishing 14.9% mean body weight loss at 68 weeks (N=1,961) used Novo Nordisk's proprietary formulation, not compounded versions [12]. No randomized controlled trial has directly compared brand Wegovy to compounded semaglutide for efficacy or safety.

"Compounded GLP-1 receptor agonists have not undergone the same rigorous testing as FDA-approved products," noted the Endocrine Society in a 2024 statement on compounded peptides [13]. Patients choosing compounded semaglutide should discuss risks with their prescriber.

Getting Wegovy via Telehealth in Massachusetts

Telehealth prescribing of Wegovy is fully legal in Massachusetts. State law permits clinicians to prescribe controlled and non-controlled medications after a synchronous audio-video visit, and semaglutide is not a controlled substance.

Several telehealth platforms operate in Massachusetts and prescribe Wegovy or compounded semaglutide. Pricing models vary: some charge a monthly membership ($99 to $199) that bundles the consultation fee with medication, while others charge a consultation fee ($50 to $150) with the prescription filled separately at a retail or compounding pharmacy.

The Massachusetts Board of Registration in Medicine requires that the prescribing clinician hold a valid Massachusetts medical license or practice under an interstate compact. The Federation of State Medical Boards (FSMB) maintains guidelines on telehealth prescribing standards that Massachusetts broadly follows [14].

Patients using telehealth for Wegovy should ensure their provider orders baseline labs, including HbA1c, renal function, and lipid panel. The American Association of Clinical Endocrinology (AACE) obesity guidelines recommend metabolic screening before initiating GLP-1 RA therapy [15]. Telehealth visits that skip lab work may not meet standard-of-care requirements.

Comparing All Wegovy Pricing Options in Massachusetts

The cost spread in Massachusetts is wide. Brand Wegovy at retail runs $1,349 per month cash. With commercial insurance and a savings card, out-of-pocket cost can drop to $0. Compounded semaglutide through a licensed 503A pharmacy averages $199 per month. Telehealth-bundled programs sit between $149 and $399 monthly depending on whether they supply brand or compounded product.

A 2023 analysis in Diabetes Care estimated that semaglutide 2.4 mg met conventional cost-effectiveness thresholds only when net prices reflected post-rebate commercial rates, not list prices [16]. For Massachusetts patients without insurance coverage, the brand product remains cost-prohibitive for most household budgets.

Here is a quick breakdown:

• Brand Wegovy, cash pay: $1,349/month
• Brand Wegovy, insured with savings card: $0 to $150/month
• Brand Wegovy, MassHealth with PA: $0 to $3.65 copay
• Compounded semaglutide 2.4 mg (503A): $150 to $250/month
• Telehealth bundle (compounded): $149 to $399/month (includes visit fee)

Patients who qualify for MassHealth and obtain prior authorization pay the lowest amount. Commercially insured patients should apply for the Novo Nordisk savings card before filling their first prescription.

Clinical Evidence Behind the Price Tag

Wegovy's pricing reflects its clinical trial portfolio. The STEP-1 trial, published in the New England Journal of Medicine, randomized 1,961 adults with BMI ≥30 (or ≥27 with comorbidity) to semaglutide 2.4 mg weekly or placebo. At 68 weeks, the semaglutide group lost 14.9% of body weight versus 2.4% in the placebo group (estimated treatment difference: −12.4 percentage points; 95% CI, −13.4 to −11.5; P<0.001) [12].

The SELECT cardiovascular outcomes trial (N=17,604) demonstrated that semaglutide 2.4 mg reduced major adverse cardiovascular events by 20% versus placebo in adults with overweight or obesity and established cardiovascular disease (HR 0.80; 95% CI, 0.72 to 0.90; P<0.001), as published in the New England Journal of Medicine in 2023 [17]. This trial led to Wegovy's supplemental FDA indication for cardiovascular risk reduction.

"The SELECT trial is a landmark because it shows that treating obesity with semaglutide reduces hard cardiovascular endpoints, not just body weight," stated Dr. A. Michael Lincoff, the trial's principal investigator, in the NEJM publication [17].

The most common adverse events across STEP trials were gastrointestinal: nausea (44%), diarrhea (30%), vomiting (24%), and constipation (24%), according to the Wegovy prescribing information [1]. Most GI side effects were mild to moderate and peaked during dose escalation. Serious adverse events, including pancreatitis and gallbladder disease, occurred at low rates but are listed as warnings in the label.

The WHO added semaglutide to its Model List of Essential Medicines in 2023 for type 2 diabetes [18]. While Wegovy's obesity indication was not specifically listed, the inclusion signals global recognition of semaglutide's therapeutic value.

Discount Programs and Patient Assistance in Massachusetts

Beyond the Novo Nordisk savings card, patients in Massachusetts can explore several additional pathways to reduce Wegovy costs.

Novo Nordisk operates a Patient Assistance Program (PAP) for uninsured patients with household incomes at or below 400% of the federal poverty level [19]. Approved applicants receive brand Wegovy at no cost. The application requires income documentation and a prescriber's signature.

Independent nonprofit foundations, such as the Patient Access Network (PAN) Foundation and the HealthWell Foundation, periodically open funding cycles for anti-obesity medications. Availability fluctuates, and Massachusetts residents should check eligibility early. The NIH's guide to prescription assistance programs lists additional resources [20].

Some Massachusetts employers have added anti-obesity medication coverage after the SELECT trial data showed cardiovascular benefit. Employees should ask their HR department whether the self-insured plan formulary was updated in the most recent plan year. A 2024 Kaiser Family Foundation employer survey found that approximately 44% of large employers covered at least one GLP-1 RA for weight management, up from 26% in 2023 [21].

Massachusetts-based academic medical centers, including Mass General Brigham and Beth Israel Lahey Health, have obesity medicine clinics with dedicated prior authorization teams. These clinics often achieve higher approval rates than primary care offices submitting PAs independently, based on their experience with appeal documentation and insurer-specific requirements.

Patients filling Wegovy at Costco pharmacies (accessible without a Costco membership in Massachusetts under state pharmacy access law) may find modestly lower cash prices compared to chain pharmacies. Comparing prices across GoodRx, RxSaver, and direct pharmacy quotes before filling is a practical first step.

The Wegovy 0.25 mg starting dose at week one of titration carries the same list price as the 2.4 mg maintenance dose, so cost-saving strategies should start before the first injection, not after reaching maintenance.